Atomi Financial Group Inc. Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Atomi Financial Group Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,122 shares of the company’s stock after purchasing an additional 2,969 shares during the period. Atomi Financial Group Inc.’s holdings in Johnson & Johnson were worth $5,864,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in JNJ. Norges Bank purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $4,071,642,000. Wellington Management Group LLP boosted its position in Johnson & Johnson by 16.4% in the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after buying an additional 3,391,657 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 16.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock worth $3,453,978,000 after buying an additional 3,139,499 shares during the period. Ninety One UK Ltd boosted its holdings in shares of Johnson & Johnson by 59.0% in the 2nd quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company’s stock valued at $980,579,000 after acquiring an additional 2,489,925 shares during the last quarter. Finally, Swedbank AB purchased a new position in shares of Johnson & Johnson during the first quarter worth $331,178,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.0 %

Shares of NYSE JNJ traded down $1.66 during mid-day trading on Tuesday, hitting $162.95. The company had a trading volume of 4,381,257 shares, compared to its average volume of 7,282,021. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $166.21. The company has a market capitalization of $392.17 billion, a PE ratio of 10.16, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The business’s 50-day simple moving average is $154.30 and its 200 day simple moving average is $153.26.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the firm earned $2.80 earnings per share. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on JNJ shares. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Finally, TD Securities decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.